Patrizia Lavia Selected Research

2- (sec- butylthio)- 6- (1- (2,6- difluorophenyl)propyl)- 5- methylpyrimidin- 4(3H)- one

1/2020	Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells.
8/2011	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrizia Lavia Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 09/2003
3	Genomic Instability 01/2020 - 03/2003
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 12/2017
1	Multiple Myeloma 01/2017
1	Liver Neoplasms (Liver Cancer) 11/2015
1	Carcinoma (Carcinomatosis) 11/2015
1	Aneuploidy (Aneuploid) 08/2014
1	Medulloblastoma 08/2014
1	Neuroblastoma 06/2012
1	Osteosarcoma (Osteogenic Sarcoma) 10/2011
1	Melanoma (Melanoma, Malignant) 08/2011
1	Carcinogenesis 01/2006
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2003

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2022 - 01/2006
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2016
4	TubulinIBA 05/2018 - 08/2014
3	Karyopherins (Importin)IBA 01/2020 - 04/2016
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 01/2006
3	Colchicine FDA LinkGeneric 05/2018 - 01/2013
2	2- (sec- butylthio)- 6- (1- (2,6- difluorophenyl)propyl)- 5- methylpyrimidin- 4(3H)- oneIBA 01/2020 - 08/2011
2	Nuclear Pore Complex Proteins (Nucleoporins)IBA 01/2020 - 08/2017
2	Reverse Transcriptase InhibitorsIBA 01/2020 - 08/2011
2	Growth InhibitorsIBA 05/2018 - 08/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2017 - 11/2015
2	Phosphotransferases (Kinase)IBA 05/2017 - 11/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 08/2014
2	MLN 8237IBA 08/2014 - 10/2011
2	Oncogene Proteins (Oncogene Protein)IBA 09/2003 - 03/2003
1	Messenger RNA (mRNA)IBA 01/2022
1	locked nucleic acidIBA 01/2022
1	efavirenz (Sustiva)FDA Link 01/2020
1	DNA Transposable Elements (Element, IS)IBA 01/2020
1	taxaneIBA 01/2020
1	PoisonsIBA 12/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2017
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 08/2017
1	ran-binding protein 2IBA 08/2017
1	Vincristine (Oncovin)FDA LinkGeneric 01/2017
1	LigandsIBA 01/2017
1	p38 Mitogen-Activated Protein KinasesIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 04/2016
1	indoleIBA 08/2015
1	Aurora KinasesIBA 08/2014
1	LuciferasesIBA 08/2014
1	PyrrolesIBA 08/2014
1	fosbretabulin (combretastatin A4)IBA 01/2013
1	compound 18IBA 01/2013
1	Tubulin ModulatorsIBA 01/2013
1	DNA (Deoxyribonucleic Acid)IBA 06/2012
1	Human immunodeficiency virus 1 reverse transcriptaseIBA 08/2011
1	NucleosidesIBA 08/2011
1	Transcription Factors (Transcription Factor)IBA 05/2008
1	GTP Phosphohydrolases (GTPases)IBA 05/2008
1	MutagensIBA 01/2006
1	Retroelements (Retrotransposon)IBA 01/2006
1	Nevirapine (Viramune)FDA Link 05/2003

Therapy/Procedure

5	Therapeutics 11/2015 - 01/2006
1	Radiotherapy 11/2015